Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

British Journal of Cancer

Volumn 93, Issue 5, 2005, Pages 552-556

  Zidan, J ^a,b   Dashkovsky, I ^a   Stayerman, C ^a   Basher, W ^a   Cozacov, C ^a   Hadary, A ^a  

^a Rebecca Sieff Government Hospital   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Comparison; HER 2 overexpression; Metastases; Primary breast cancer; Treatment

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CONFIDENCE INTERVAL; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; TUMOR BIOPSY; BREAST TUMOR; CANCER STAGING; CASE REPORT; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; LUNG CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 26944465031     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602738     Document Type: Article

References (37)

1. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D (1998) Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4): 1340-1349
2. Baselga J (2001) Phase I and II clinical trials of trastuzumab. Ann Oncol 12(Suppl 1): 49-55
3. Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, Naldi N, Cascinu S (2002) HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 13: 1398-1403
4. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander Jr RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889-2895
5. Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferreira F, Paesmans M, Piccart M (2001) Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12: 615-620
6. Cobleigh M, Vogel CH, Tripathy D (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
7. Dandachi N, Dietze O, Hauser-Krongberg C (2004) Evaluation of the clinical significance of HER-2 amplification by chromogenic in situ hybridization in patients with primary breast cancer. Anticancer Res 24: 2401-2406
8. Dowsett M, Gutierrez C, Mohsin S, Schiff R, Detre S, Johnston S, Osborne CK (2003) Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2, and p38 MAP-Kinase. Proc Am Soc of Clin Oncol 22: 3 (Abstract 7)
9. Edgerton SE, Merkel D, Moore DH, Thor AD (2000) HER-2/neu/erB-b2 status by immunohistochemistry and FISH: clonality and progression with recurrence and metastases. Breast Cancer Res Treat 64: 55
10. Eiermann W (2001) The International Trastuzumab Study Group. Trastuzumab combined with chemotherapy for the treatment of HER-2 positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(Suppl 1): 57-62
11. Elledge R, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7-12
12. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-1043
13. Hamilton A, Piccart M (2000) The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11: 647-663
14. Harris J, Morrow M, Norton L (1997) Malignant tumors of the breast. In Cancer: Principles and Practice of Oncology, DeVita Jr VT, Hellman S, Rosenberg SA (eds), 5th edn pp 1557-1616. Philadelphia: Lippincott-Raven
15. Hortobagyi G (2001) Optimal duration therapy with trastuzumab. Semin Oncol 28(Suppl 18): 1-2
16. Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57: 1597-1604
17. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A (1995) Elevated serum c-erb-B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135
18. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Lang R, Hackl W, Hamer P, Carney W (2003) Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs tamoxifen. Proc Am Soc Clin Oncol 22: 3 (Abstract 8)
19. Lohrisch C, Piccart M (2001) An overview of HER-2. Semin Oncol 28(Suppl 18): 3-11
20. Luftner D, Dilk H, Henschke P, Geppert R, Dietel M, Stein H, Wernecke K, Possinger K, Heine P (2004) Results of a 10-year retrospective search in two university institutes of pathology: Concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases. Proc Am Soc Clin Oncol 23(14S): 44 (Abstract 670)
21. Masood S, Bui MM (2000) Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30: 259-265
22. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW (1993) Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023
23. Niehans GA, Singleton TP, Dykoski D, Kiang DT (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85: 1230-1235
24. No author listed (1999) Detection of HER2/neu (c-erbB-2) Antigen Overexpression: An NCI Symposium. Bethesda, MD: Lippincott, October 7-8
25. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N (1998) erb-B2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370
26. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3: 237-252
27. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, Sugihara K (2000) c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73: 17-20
28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
29. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
30. Slichenmyer W, Fry D (2001) Anticancer therapy targeting the Erb B family of receptor tyrosine kinases. Semin Oncol 28: 67-79
31. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase II-α in primary and metastatic breast cancer. Cancer Res 61: 5345-5348
32. Teixeira MR, Pandis N, Bardi G, Andersen JA, Mitelman F, Heim S (1995) Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int J Cancer 63: 63-68
33. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET (1998) erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360
34. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshda T, Skamoto H, Terada M, Sugimura T (1989) Correlation between long term survival in breast cancer patients and amplification of two putative oncogene co-amplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104-3108
35. Vogel C, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S, Shak S (2001) First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 19: 71a (Abstract 275)
36. Zidan J, Dashkovsky I, Cozacov C, Hadary A, Basher W (2002) Comparison of HER-2 in primary breast cancer and metastatic sites and its effect on treatment of metastatic disease. ESMO 2002 Ann Oncol 13(Suppl 5): 50 (Abstract 179P)
37. Zidan J, Dashkovsky I, Hadary A, Basher W, Cozacov C (2004) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Proc Am Soc of Clin Oncol 23: 40 (Abstract 655)